About Allovir (ALVR)
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to r... Read more
- USD0.75
- USD0.77
- USD0.73
- USD2.54
- 2.30%
- --
- 341.10k
- 163.36k
- 87M
- 0.58
- -64.70%
Stock News
2 hours ago
Insurance giant CEO shares the No. 1 piece of career advice that helped her get ahead—it's 'especially' important right now
CNBC
2 hours ago
Bond spreads for ‘Magnificent Seven’ tighten as investors celebrate interest-rate cut
MarketWatch
2 hours ago
Don't let Abbott Labs' litigation overhang keep you out of the stock
CNBC
2 hours ago
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Yahoo
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
